Amarantus BioScience Holdings, Inc.
AMBS
Rank in Stocks
#34034
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Share Price
$0.0001
Last synced: 2026-11-10
Market Cap
$63.04K
Change (1 day)
0.00%
Change (1 year)
-66.67%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Amarantus BioScience Holdings, Inc. (AMBS)
Category
Healthcare
Operating Margin for Amarantus BioScience Holdings, Inc. (AMBS)
Operating Margin as of November 2026 TTM: -281.13%
According to Amarantus BioScience Holdings, Inc.'s latest financial reports, its current operating margin (TTM) is -281.13%. At the end of 2022 the company had an operating margin of -281.13%.
Operating Margin history for Amarantus BioScience Holdings, Inc. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -281.13% | 0.00% |
| 2022 | -281.13% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -840.70% | -1,017.39% |
| 2019 | 91.64% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | -100.00% |
| 2011 | -1,672.72% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -1,660.10% | -89.89% |
| 2008 | -16,424.29% | 209.56% |
| 2007 | -5,305.63% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.14% |
US
|
|
| -149.01% | -99.47% |
US
|
|
| 25.57% | -100.09% |
AU
|
|
| 31.23% | -100.11% |
BE
|
|
| 29.35% | -100.10% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Amarantus BioScience Holdings, Inc.'s operating margin
What is Amarantus BioScience Holdings, Inc.'s operating margin?
Amarantus BioScience Holdings, Inc.'s operating margin is -281.13%, as of Nov 2026.
What was Amarantus BioScience Holdings, Inc.'s operating margin in 2022?
In 2022, Amarantus BioScience Holdings, Inc.'s operating margin was -281.13%, compared with 0.00% in 2021.
How has Amarantus BioScience Holdings, Inc.'s operating margin changed since 2017?
From 2017 to 2022, Amarantus BioScience Holdings, Inc.'s operating margin was highest in 2019 (91.64%) and lowest in 2020 (-840.70%).
How does Amarantus BioScience Holdings, Inc.'s operating margin compare with similar companies?
Amarantus BioScience Holdings, Inc.'s operating margin (-281.13%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.